WallStSmart

Cencora Inc. (COR)vsSanofi ADR (SNY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Cencora Inc. generates 594% more annual revenue ($328.68B vs $47.35B). SNY leads profitability with a 16.0% profit margin vs 0.8%. COR appears more attractively valued with a PEG of 0.73. COR earns a higher WallStSmart Score of 64/100 (C+).

COR

Buy

64

out of 100

Grade: C+

Growth: 7.3Profit: 6.0Value: 8.0Quality: 5.0

SNY

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 6.5Value: 5.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CORUndervalued (+71.1%)

Margin of Safety

+71.1%

Fair Value

$1266.50

Current Price

$261.08

$1005.42 discount

UndervaluedFair: $1266.50Overvalued
SNYUndervalued (+24.9%)

Margin of Safety

+24.9%

Fair Value

$62.64

Current Price

$43.31

$19.33 discount

UndervaluedFair: $62.64Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

COR4 strengths · Avg: 9.0/10
Return on EquityProfitability
107.1%10/10

Every $100 of equity generates 107 in profit

EPS GrowthGrowth
128.3%10/10

Earnings expanding 128.3% YoY

PEG RatioValuation
0.738/10

Growing faster than its price suggests

Free Cash FlowQuality
$1.17B8/10

Generating 1.2B in free cash flow

SNY4 strengths · Avg: 8.8/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

Market CapQuality
$103.45B9/10

Large-cap with strong market position

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$1.68B8/10

Generating 1.7B in free cash flow

Areas to Watch

COR4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
3.8%4/10

3.8% revenue growth

Profit MarginProfitability
0.8%3/10

0.8% margin — thin

Operating MarginProfitability
1.7%3/10

Operating margin of 1.7%

Price/BookValuation
26.6x2/10

Trading at 26.6x book value

SNY3 concerns · Avg: 2.3/10
Return on EquityProfitability
6.6%3/10

ROE of 6.6% — below average capital efficiency

PEG RatioValuation
3.762/10

Expensive relative to growth rate

EPS GrowthGrowth
-11.7%2/10

Earnings declined 11.7%

Comparative Analysis Report

WallStSmart Research

Bull Case : COR

The strongest argument for COR centers on Return on Equity, EPS Growth, PEG Ratio. PEG of 0.73 suggests the stock is reasonably priced for its growth.

Bull Case : SNY

The strongest argument for SNY centers on Price/Book, Market Cap, Operating Margin. Profitability is solid with margins at 16.0% and operating margin at 20.0%.

Bear Case : COR

The primary concerns for COR are Revenue Growth, Profit Margin, Operating Margin. Thin 0.8% margins leave little buffer for downturns.

Bear Case : SNY

The primary concerns for SNY are Return on Equity, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

COR profiles as a value stock while SNY is a mature play — different risk/reward profiles.

COR carries more volatility with a beta of 0.65 — expect wider price swings.

SNY is growing revenue faster at 6.0% — sustainability is the question.

SNY generates stronger free cash flow (1.7B), providing more financial flexibility.

Bottom Line

COR scores higher overall (64/100 vs 51/100). SNY offers better value entry with a 24.9% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cencora Inc.

HEALTHCARE · MEDICAL DISTRIBUTION · USA

CoreSite Realty Corporation (NYSE: COR) delivers secure, reliable, high-performance data center, cloud access and interconnect solutions to a growing client ecosystem in eight key North American markets.

Sanofi ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.

Want to dig deeper into these stocks?